Comments by "ARK CON" (@arkcon714) on "No shortage of support for “Freedom Convoy” despite frigid temperatures" video.
-
23
-
11
-
@darylbenson9682 Paxil, Wellbutrin, Avandia all fully approved by the FDA, all caused major health problems and were sued
Bextra, Geodon, Zyvox, Lyrica
Again, all FDA approved
Risperdal, Invega, Natrecor you guessed it, all FDA approved!
Depakote, Seroquel all FDA approved
So as you can plainly see FDA approval is meaningless
Here's a list of some of the larger suits in the past decade or so
Glaxo Smith Kline $3 billion 2012
Pfizer $2.3 billion 2009
Johnson & Johnson $2.2 billion 2013
Abbott $1.5 billion 2012
Eli Lilly $1.42 billion 2009
Merck $950 million 2011
Amgen $762 million 2012
AstraZeneca $520 million 2010
Actelion $360 million 2018
Purdue Pharma $270 million 2019
This vax they ensured legislation was in place to protect them from liability and even wanted to keep the trial data secret for 75 years, why would anyone doubt their honorable intentions?
5
-
3
-
@darylbenson9682 nothing you just said is even remotely accurate and is based on media nonsense not science or data.
Background The incidence of (redacted) infection, including among those who have received 2 doses of (redacted) vaccines, has increased substantially since Omicron was first identified in the province of Ontario, Canada.
Methods Applying the test-negative design to linked provincial data, we estimated vaccine effectiveness against infection (irrespective of symptoms or severity) caused by Omicron or Delta between November 22 and December 19, 2021. We included individuals who had received at least 2 (redacted) vaccine doses (with at least 1 mRNA vaccine dose for the primary series) and used multivariable logistic regression to estimate the effectiveness of two or three doses by time since the latest dose.
Results We included 3,442 Omicron-positive cases, 9,201 Delta-positive cases, and 471,545 test-negative controls. After 2 doses of (redacted) vaccine, vaccine effectiveness against Delta infection declined steadily over time but recovered to 93% (95%CI, 92-94%) ≥7 days after receiving an mRNA vaccine for the third dose. In contrast, receipt of 2 doses of (redacted) vaccines was not protective against Omicron. Vaccine effectiveness against Omicron was 37% (95%CI, 19-50%) ≥7 days after receiving an mRNA vaccine for the third dose.
Conclusions Two doses of COVID-19 vaccines are unlikely to protect against infection by Omicron. A third dose provides some protection in the immediate term, but substantially less than against Delta. Our results may be confounded by behaviours that we were unable to account for in our analyses. Further research is needed to examine protection against severe outcomes.
2
-
2
-
1
-
1